Incyte gets green light for new eczema cream – and a warning

A topical version of Incyte's eczema drug ruxolitnib has passed through the eye of the needle at the FDA, but a warning has been issued regarding its drug class.
Photo: Andrew Kelly/REUTERS / X02844
Photo: Andrew Kelly/REUTERS / X02844
by elizabeth mønsted johansen, translated by catherine brett

After an extended assessment period, the FDA has ruled on Incyte's topical formulation of eczema treatment ruxolitnib.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading